logo
Twitter
Discord
Email
logo
Fresenius Medical Care AG

Fresenius Medical Care AG

NYSE•FMS
CEO: Ms. Helen Giza
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1996-09-17
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Contact Information
Else-KrOener-Strasse 1, Bad Homburg, 61352, Germany
49-6172-609-0
www.freseniusmedicalcare.com
Market Cap
$13.70B
P/E (TTM)
17.9
16
Dividend Yield
3.4%
52W High
$30.46
52W Low
$22.05
52W Range
16%
Rank39Top 29.7%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$5.71B+2.62%
4-Quarter Trend

EPS

$0.55+27.03%
4-Quarter Trend

FCF

$642.16M-32.95%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Net Income Attributable Growth Net income attributable to shareholders grew 9% (Constant Currency) to €538 M, driven by growth and savings.
Operating Income Rises Operating income increased 3% (Constant Currency) to €1.392 B, benefiting from organic growth across segments.
Care Enablement Swings Profit Care Enablement operating income swung to €267 M profit, reversing prior year loss due to growth and remeasurements.
FME25 Savings Realized Recurring FME25 Program savings reached €567 M in 2024, offsetting negative impacts from portfolio optimization activities.

Risk Factors

Regulatory Reform Uncertainty Potential legislative reform creates uncertainty and threats to operating models, especially concerning U.S. reimbursement structures.
Inflationary Cost Pressures Increased labor, energy, and raw material costs continue to pressure margins, potentially offsetting cost savings initiatives.
Goodwill Impairment Sensitivity Substantial goodwill (€15.17 B) remains sensitive to macroeconomic changes affecting WACC and future cash flow projections.
Cybersecurity Threat Exposure Increased digital data storage heightens exposure to cyber-attacks, data breaches, and potential litigation risks.

Outlook

HVHDF U.S. Market Entry Planning limited launch of High-Volume Hemodiafiltration (HVHDF) in targeted U.S. clinics starting in 2025.
Continue FME25 Optimization Focus remains on achieving projected cost savings through 2025 by streamlining operations and optimizing footprint.
Sustainability Target Submission Developing Scope 3 GHG emission targets aligned with SBTi criteria, planned for submission and publication in 2025.
Core Business Focus Strategy centers on exiting non-core assets and focusing capital allocation towards core kidney care growth areas.

Peer Comparison

Revenue (TTM)

Fresenius Medical Care AGFMS
$21.68B
+2.1%
Tenet Healthcare CorporationTHC
$20.86B
-0.6%
Universal Health Services, Inc.UHS
$16.99B
+10.2%

Gross Margin (Latest Quarter)

Royalty Pharma plcRPRX
100.0%
+0.0pp
Incyte CorporationINCY
92.8%
+1.8pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
INCY$18.72B15.729.8%0.6%
THC$17.36B12.833.6%44.8%
HOLX$16.68B29.711.7%27.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.7%
Moderate Growth
4Q Net Income CAGR
65.1%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:$0.74
|
Revenue:-
Reports
All Years
  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $20.92B-0.6%
    |
    EPS: $1.00+7.6%
    Beat
  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 20, 2024|
    Revenue: $21.04B+0.3%
    |
    EPS: $0.92-26.1%
    Beat
  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Feb 22, 2023|
    Revenue: $20.39B+10.1%
    |
    EPS: $1.21-30.5%
    Beat
  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Feb 22, 2022|
    Revenue: $20.83B-1.3%
    |
    EPS: $1.96-16.4%
    Miss
  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Feb 23, 2021|
    Revenue: $20.37B+2.2%
    |
    EPS: $2.26+0.0%
    Miss